Cell and gene therapy access expands into community care settings only when operational coordination, site readiness, and supply chain standardization become first-order priorities equivalent to ...
In today's ACT Brief, we examine understanding the patient journey from end to end, whether decentralization reduces site ...
In part two of her DPHARM interview, Andrea Valente, CEO of uMotif, explains why the real technology challenge isn't ...
In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale.
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system ...
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale. AI adoption is moving quickly in life sciences, ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 trials, undermining assumptions that any single model is inherently superior.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results